These products will explode in 2017, with a total revenue of over 100 billion!

According to the forecast of cortellis competitive intelligence database, 9 of the new drugs to be launched in 2017 will reach the blockbuster level (with annual sales of more than US $1 billion) or close to this level within 5 years, and 7 of them have submitted applications to FDA in various forms of accelerated review Whether from the perspective of meeting clinical needs or creating business value, these nine drugs are the most concerned drugs worthy of 2017 In 2017, the pharmaceutical industry is bound to be different from other times At the beginning of the year, several opinions on further reform and improvement of drug circulation and use policy (hereinafter referred to as "document 13") was issued, which has become a major policy at the top level of design Later, e drug managers learned that, at the request of the State Council, document 13 was broken down into 58 specific contents, and attention was paid to defining the implementation departments Among them, there are two contents led by the medical reform office: improving research and development ability, including innovation ability and quality of generic drugs At the national level, pharmaceutical innovation is no longer a slogan, but is actually implemented as a national strategy, and is inclined to innovative drugs in policy-making Previously, the whole industry was making great changes on the issue that innovative drugs could not be connected with medical insurance after being listed According to e-drug managers, innovative drugs will be connected with medical insurance in the form of drug price negotiation at the national level China's pharmaceutical industry is also gradually changing from "sales driven" to "R & D driven", and is docking with the world at a fast pace From the perspective of global innovative drugs, in the past few years, there has been a trend of fatigue in the research and development of innovative drugs in the global market After accumulation, 2017 will be a time when a number of heavy products will break out Many of them are called epoch-making products, which will provide a reference space for China's research and development and an earlier layout E drug managers gathered all kinds of news and found that the following nine varieties are the most interesting varieties in 2017, which will drive the global pharmaceutical growth with technical force, and with the acceleration of drug audit reform, these products will enter the domestic market at a faster speed In terms of the current situation, the drug Watch report expects total revenue to reach US $16 billion Notes on the most anticipated sales of nine drugs in 2017: the chart information comes from corellion 1 Company of ocreuvs: on March 29, 2017, the FDA approved the antibody of Roche CD20 and the drug ocrelizumab (trade name ocrevus) for the treatment of recurrent (RRMS) and primary progressive (PPMS) sclerosis Ocrevus was approved as the first PPMs drug to go on the market According to analysts, the sales volume of the product in five years is 4 billion US dollars At present, there are about 2 million patients with multiple sclerosis in the world, most of them are RRMS Although the efficacy of ocrevus is not subversive, it has changed the situation that PPMs has no medicine to treat Previously, RRMS was mainly controlled by drug use outside the label PPMs is a very malignant disease, and there is no progress in treatment for decades Ocrevus is a breakthrough Ocrevus is priced at US $65000 per year, which is 25% cheaper than the drugs currently used outside the label, which improves its competitive advantage by rapidly occupying the market According to the director of Neurology Products Department of FDA drug evaluation and Research Center, "this treatment not only provides another treatment option for patients with relapsed MS, but also provides another treatment option for those with primary progressive multiple sclerosis for the first time." 2 Dupixent's company: Sanofi / Zaiyuan on March 28, 2017, Sanofi and Zaiyuan announced that FDA approved its new eczema drug dupilumab For adults with moderate to severe eczema (atopic dermatitis, AD) treated by injection, dupilumab is suitable for eczema that is not fully controlled by local treatment, or for patients who are not suitable for local treatment Dupilumab is the first approved targeted biopharmaceutic for the above indications It is designed to specifically inhibit the over signaling of two key proteins, interleukin-4 (IL-4) and interleukin-3 (IL-13), which are considered to be the main drivers of persistent underlying inflammation in AD Dupilumab is considered to be a game changing drug as a single therapy in the clinical trials of solo 1 and solo 2 Compared with placebo, dupilumab can significantly improve the symptoms of atopic dermatitis, including pruritus, anxiety and depression, and quality of life Sales are expected to exceed $4 billion in 2022 3 Company of durvalumab: AstraZeneca At the end of last year, AstraZeneca and its global biologics R & D company, MedImmune, announced that FDA has accepted durvalumab, PD-L1 monoclonal antibody (mAb) application, which is the company's first biologics licensing application (BLA), and has granted priority review qualification of prescription drug user fee Act (PDUFA), which will be reviewed in the second quarter of 2017 In recent years, in the field of tumor immunotherapy, PD-1 / PD-L1 has attracted much attention, especially after kestruda of moshadong took the lead in the first-line treatment of NSCLC, which has attracted numerous hero competitions However, the combination of AstraZeneca's PD-L1 monoclonal antibody durvalumab and CTLA-4 monoclonal antibody tremelimumab in the first-line treatment of NSCLC has made the market expect and imagine more At present, 70 different target drugs of PD-1 / PD-L1 are in the research and development stage around the world At home, there are many enterprises in Shanghai Junshi, Jiangsu Hengrui, Baiji Shenzhou, Xinda biology, Sansheng pharmaceutical and so on 4 Semaglutide company: at the end of last year, Novo Nordisk, a diabetes giant, announced that it would submit a new drug application (NDA) for the new diabetes drug semaglutide (somalutide) to the FDA, as well as an application for marketing license to the European drug administration Semaglutide is a new type of long-acting glucagon like peptide-1 (GLP-1) analogue Subcutaneous injection once a week can significantly improve the blood glucose level in patients with type 2 diabetes and reduce the risk of hypoglycemia At the same time, semaglutide can also induce weight loss by reducing appetite and food intake In addition, semaglutide can significantly reduce the risk of major cardiovascular events (MACE) in patients with type 2 diabetes The data showed that semaglutide was significantly better than januvia (genovue, general name: sitagliptin, sitagliptin), bydureon (exenatide), a GLP-1 receptor agonist of AstraZeneca, in lowering blood glucose and maintaining blood glucose control Er, exenatide sustained release, weekly subcutaneous injection), Sanofi world's best-selling insulin products (insulin glargine U100) and placebo The industry is also optimistic about the future of semaglutide, which is believed to help Novo Nordisk maintain its leading position in the fast-growing global diabetes market Analysts at ALM brand bank predict that semaglutide will reach a peak of $4.6-5.3 billion in sales by 2030 5 Company of lumiant: Lilly / Incyte Olumiant is a new rheumatoid drug jointly developed by Lilly and its partner Incyte In February 2017, 4mg and 2mg film coated tablets were approved by the European Union As a single drug or combined with methotrexate, olumiant is used to treat adult patients with moderate to severe active rheumatoid arthritis (RA) with insufficient or intolerable remission of one or more modified anti rheumatic drugs (DMARD) The drug is a selective and reversible inhibitor of Jak1 and JAK2 In fact, Lilly's cooperation with Incyte on the drug started as early as 2009, while the latest approval in the EU is based on the positive data of four phase III studies completed in the phase III clinical project of the drug, showing its efficacy and safety in a wide range of adult patients with moderate to severe active rheumatoid arthritis (RA) In October 2016, in a key phase III study In addition, it was also found to be significantly better than the heavyweight anti-inflammatory drug Humira (adalimumab) of ibuprofen in improving the symptoms and signs of RA It is worth noting that this EU approval is also the first regulatory approval received by olulant worldwide, and also the first JAK inhibitor approved by EU for the treatment of rheumatoid arthritis (RA) According to the prediction of clarivate analytics, olumiant will achieve sales revenue of $145 million in 2017, and by 2021, its sales will break the 1 billion mark to reach $1.283 billion 6 Ribociclib's company: according to the information on the FDA website, on March 13, 2017, the new drug ribociclib (lee11), a double inhibitor of CDK, developed by Novartis, has been successfully listed It is a selective inhibitor of cyclin dependent kinase, which can slow down the progression of cancer by inhibiting CDK4 / 6 It is mainly used in combination with letrozole as a first-line drug for the treatment of HR positive / HER2 negative postmenopausal women with advanced breast cancer Previously, on November 2, 2016, the FDA granted the accelerated review of the drug, and the European Drug Administration accepted its new drug application for the same indication The drug is undoubtedly a new drug of great commercial value Previously, the development of new drugs for CDK inhibitors has been slow Pfizer did not fully promote the clinical development of its oral and selective CDK4 / 6 inhibitor, palbociclib, until 2009 On February 3, 2015, Pfizer obtained the FDA's accelerated approval for listing (trade name: ibrance) When it was launched, it achieved great commercial success, with sales revenue of up to $723 million in the year of listing And ribociclib is regarded as the most promising product to compete with Pfizer's ibrance, but because they are very similar in structure, and the indications for declaration in the United States are the same, and ribociclib is two years late to go on the market, so its sales expectation is far lower than that of ibrance 7 Avelumab's company: Merck / Pfizer Avelumab is a lgg1 antibody (PD-L1) developed by German pharmaceutical giant Merck and American pharmaceutical giant Pfizer The latest development of the drug is that the FDA of the United States has officially accepted the license application of the drug for the treatment of local advanced or metastatic urothelial cancer during or after chemotherapy with platinum, and has also been granted the priority review qualification Its review week The period will be shortened from 10 months to 6 months At the end of November 2016, the FDA officially accepted the application for the license of biological products for the treatment of metastatic Merkel cell carcinoma, and also granted the priority review qualification Merkel cell carcinoma is a rare invasive skin cancer with a very poor prognosis and a 5-year survival rate of less than 20% At present, there is no drug for the treatment of metastatic MCC Once approved, avelumab will become the first PD-1 / PD-L1 immunotherapy for Merkel cell carcinoma in the world, and achieve a "zero" breakthrough in regulatory approval It is reported that the cooperation agreement on PD-1 / PD-L1 immunotherapy signed between Pfizer and Merck amounts to US $2.85 billion, which is naturally a high market peak in this field It is worth noting that avelumab has gained the status of orphan medicine in the United States 8 Niraparib's company: on July 1, 2016, the stock of teslo, a biotech company based in Boston, USA, soared more than twice, from $37 to $77 in a flash, all because of the release of phase III clinical trial data of niraparib, a new anticancer drug developed by the company Niraparib is an oral drug targeting PARP gene